SEARCH

SEARCH BY CITATION

References

  • 1
    Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983988.
  • 2
    Guyatt GH, Akl EA, Crowther M, et al. Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141:7S47S.
  • 3
    Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133:546S592S.
  • 4
    Ma TK, Yan BP, Lam YY. Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data. Pharmacol Ther. 2011;129:185194.
  • 5
    Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet. 2008;47:285295.
  • 6
    Hong Kong Hospital Authority. Hospital authority drug formulary 2005 [updated January 14, 2012]. http://www.ha.org.hk/hadf/. Accessed April 16 2012.
  • 7
    Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:11391151.
  • 8
    Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation. 2011;123:25622570.
  • 9
    Langkilde LK. Cost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clinical practice in Denmark. J Med Econ. 2012;15:19.
  • 10
    Sorensen SV, Kansal AR, Connolly S, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Thromb Haemost. 2011;105:908919.
  • 11
    Freeman JV, Zhu RP, Owens DK, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med. 2011;154:111.
  • 12
    Kansal AR, Sorensen SV, Gani R, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation. Heart. 2012;98:573578.
  • 13
    Pink J, Lane S, Pirmohamed M, et al. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses. BMJ. 2011;343:d6333.
  • 14
    Ho JC, Chang AM, Yan BP, et al. Dabigatran compared with warfarin for stroke prevention with atrial fibrillation: experience in Hong Kong. Clin Cardiol. 2012;35:E40E45.
  • 15
    Hong Kong SAR. Hong Kong Government Gazette No. 13/2003 S.S. No. 4. Hong Kong: Hong Kong SAR Government; 2003.
  • 16
    Prince of Wales Hospital. Drug formulary. Hong Kong: Hospital Authority; 2011.
  • 17
    Hong Kong Hospital Authority. Hospital Authority annual report 2010/11. Hong Kong: Hospital Authority; 2011.
  • 18
    Brumley R, Enguidanos S, Jamison P, et al. Increased satisfaction with care and lower costs: results of a randomized trial of in-home palliative care. J Am Geriatr Soc. 2007;55:9931000.
  • 19
    Liu L, Cowen ME, Strawderman RL, et al. A flexible two-part random effects model for correlated medical costs. J Health Econ. 2010;29:110123.
  • 20
    Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thrombost Haemost. 2005;3:692694.
  • 21
    Fung JWH. An update in AF management. Hong Kong Med Bull. 2011;16:46.